Current concepts in the pharmacological management of obesity

Drugs

Volumn 57, Issue 6, 1999, Pages 883-904

  Carek, Peter J ^a,b   Dickerson, Lori M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; DEXFENFLURAMINE; EPHEDRINE; FENFLURAMINE; LEPTIN; NEUROPEPTIDE Y; PHENTERMINE; PHENYLPROPANOLAMINE; SIBUTRAMINE; SUCROSE POLYESTER; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE;

BODY WEIGHT; CALORIC INTAKE; CARDIOVASCULAR RISK; DIET; ENERGY EXPENDITURE; ENZYME INHIBITION; EXERCISE; FAT INTAKE; FAT SUBSTITUTE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; LIPID ABSORPTION; MORTALITY; OBESITY; RESPIRATORY TRACT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; WEIGHT GAIN; WEIGHT REDUCTION;

APPETITE DEPRESSANTS; DIGESTION; HORMONES; HUMANS; HYPERTHERMIA, INDUCED; LEPTIN; NEUROPEPTIDE Y; OBESITY; PROTEINS;

EID: 0032966804     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957060-00005     Document Type: Review

References (125)

1. 1. Gray DS. Diagnosis and prevalence of obesity. Med Clin North Am 1989; 73: 1-13
2. 2. Kuczmarski RJ, Flegal KM, Campbell SM, et al. Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994; 272: 205-11
3. 3. Levy SL, Heaton AW. Weight control practices of U.S. adults trying to lose weight. Ann Intern Med 1993; 119: 661-6
4. 4. Serdula MK, Collins ME, Williamson DF, et al. Weight control practices of US adolescents and adults. Ann Intern Med 1993; 119: 667-71
5. 5. Bray GA. Obesity: definition, diagnosis, and disadvantages. Med J Aust 1985; 142 Suppl.: S2-8
6. 6. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med 1993; 119: 655-60
7. 7. Van Itallie TB. Health implications of overweight and obesity in the United States. Ann Intern Med 1985; 103: 983-8
8. 8. United States National Commission on Diabetes. Report of the National Commission on Diabetes to the Congress of the United States. Bethesda (MD): U.S. Department of Health, Education and Welfare; 1975. Publication no.: 76-1021; Vol. I
9. 9. Garfinkel L. Overweight and cancer. Ann Intern Med 1985; 103: 1034-6
10. 10. Colditz GA. Economic costs of obesity. Am J Clin Nutr 1992; 55: 503S-7S
11. 3-adrenergic receptor and an increased capacity to gain weight in patients with morbic obesity. N Engl J Med 1995; 333: 352-4
12. 3-adrenergic receptor - a cause and cure for obesity. N Engl J Med 1995; 333: 382-3
13. 13. Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med 1993; 119: 707-13
14. 14. NIH consensus statement covers treatment of obesity. Am Fam Phys 1991; 44: 305-6
15. 15. Stunkard AJ, Craighead LW, O'Brien R. Controlled trial of behaviour therapy, pharmacotherapy, and their combination in the treatment of obesity. Lancet 1980; I: 1045-7
16. 16. Cerulli J, Lomaestro BM, Malone M. Update on the pharmacotherapy of obesity. Ann Pharmacother 1998; 32: 88-102
17. 17. Rosenbaum M, Leibel RL, Hirsch J. Obesity. N Engl J Med 1997; 337: 396-407
18. 18. Weiser M, Frishman WH, Michaelson D, et al. The pharmacologic approach to the treatment of obesity. J Clin Pharmacol 1997; 37: 453-73
19. 19. Ryan DH. Medicating the obese patient. Endocrinol Metab Clin North Am 1996; 25: 989-1004
20. 20. Bray GA. Evaluation of drugs for treating obesity. Obes Res 1995; 3 Suppl. 4: 425S-34S
21. 21. Goldstein DJ, Potvin JH. Long term weight loss: the effect of pharmacologic agents. Am J Clin Nutr 1994; 60: 647-57
22. 22. Bray GA. Drug treatment of obesity. Am J Clin Nulr 1992; 55: 538S-44S
23. 23. Björntorp P. Regional patterns of fat distribution. Ann Intern Med 1985; 103: 994-5
24. 24. Jung RT, Chong P. The management of obesity. Clin Endocrinol 1991; 35: 11-20
25. 25. Silverstone T. Appetite suppressants: a review. Drugs 1992; 43: 820-36
26. 26. Hoebel BG, Krauss IK, Cooper J, et al. Body weight decreased in humans by phenypropanolamine taken before meals. Obes Bar Med 1975; 4: 200-6
27. 27. Altschuler S, Frazer DL. Double-blind clinical evaluation of the anorectic activity of phenylpropanolamine hydrochloride drops and placebo drops in the treatment of exogenous obesity. Curr Ther Res 1986; 40: 211-7
28. 28. Griboff SI, Berman R, Silverman HI. A double-blind clinical evaluation of a phenylpropanolamine-caffeine-vitamin combination and a placebo in the treatment of exogenous obesity. Curr Ther Res 1975; 17: 535-43
29. 29. Weintraub M, Ginsberg G, Stein EC, et al. Phenylpropanolamine OROS (Acutrim) vs. placebo in combination with caloric restriction and physician-managed behaviour modification. Clin Pharmacol Ther 1986: 39: 501-9
30. 30. Greenway F. A double-blind clinical evaluation of the anorectic activity of phenylpropanolamine versus placebo. Clin Ther 1989; 11: 584-9
31. 31. Schteingan DE. Effectiveness of pheylpropanolamine in the management of moderate obesity. Int J Obesity 1992; 16: 487-93
32. 32. Munro JF, MacCuish AC, Wilson EM, et al. Comparison of continuous and intermittent anorectic therapy in obesity. BMJ 1968; 1: 352-4
33. 33. Campbell C, Bhalla IP, Steel IM, et al. A controlled trial of phentermine in obese diabetic patients. Practitioner 1977; 218: 851-5
34. 34. Tuominen S, Hietula M, Kuusankoski M. Double-blind trial comparing fenfluramine, phentermine and dietary advice on treatment of obesity. Int J Obes 1990; 14 Suppl. 2: 138
35. 35. Weintraub M, Hasday JD, Mushlin Al, et al. A double-blind clinical trial in weight control: use of fenfluramine and phentermine alone and in combination. Arch Intern Med 1984; 144: 1143-8
36. 36. Scalfi L, D'Arrigo E, Carredente V, et al. The acute effect of dexfluramine on resting metabolic rate and post prandial thermogenesis in obes subjects: a double-blind placebo-controlled study. Int J Obes Relat Metab Disord 1993; 17: 91-6
37. 37. Weintraub M. Sundaresan PR, Madan M, et al. Long term weight control study I (weeks 0 to 34): the enhancement of behaviour modification, caloric restriction, and exercise by fentluramine puse phentermine versus placebo. Clin Pharmacol Ther 1992; 51: 586-94
38. 38. Weintraub M, Sundaresan PR, Schuster B, et al. Long term weight control study (weeks 34 to 104): an open-label study of continuous felfluramine plus phentermine versus targeted intermittent medications as adjuncts to behaviour modification, caloric restriction, and exercise. Clin Pharmacol Ther 1992; 51: 595-601
39. 39. Weintraub M, Sundaresan PR, Schuster B, et al. Long term weight control study III (weeks 104 to 156): an open label study of dose adjustment of fenfluramine and phentermine. Clin Pharmacol Ther 1992; 51: 602-7
40. 40. Weintraub M, Sundaresan PR, Schuster B, et al. Long term weight control study IV (weeks 156-190): the second double blind phase. Clin Pharmacol Ther 1992; 51: 608-14
41. 41. Weintraub M, Sundaresan PR, Schuster B, et al. Long term weight control study V (weeks 190-210): follow up of participants after cessation of medication. Clin Pharmacol Ther 1992; 51: 615-8
42. 42. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581-8
43. 43. Graham DJ, Green L. Further cases of valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 635
44. 44. Centers for Disease Control and Prevention. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendation, November 1997. MMWR 1997; 46 (45): 1061-6
45. 45. Graham DJ, Green L. Further cases of valvular heart disease associated with dexfenfluramine. N Engl J Med 1997; 337: 636
46. 46. Davis R, Faulds D. Dexfenfluramine: an updated review of its therapeutic use in the management of obesity. Drugs 1996; 52: 696-724
47. 47. McTavish D, Heel RC. Dexfenfluramine: a review of its pharmacological properties and therapeutic potential in obesity. Drugs 1992; 43: 713-33
48. 48. Guy-Grand B, Apfelbaum M, Crepaldi G, et al. International trial of long term dexfenfluramine in obesity. Lancet 1989; II: 1142-4
49. 49. Wiley KA, Molyneaux I.M, Overland JE, et al. The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes. Diabet Med 1992; 9: 341-3
50. 50. Manning RM, Jung RT, Leese GP, et al. The comparison of four weight reduction strategies aimed at overweight diabetic patients. Diabet Med 1995; 12: 409-15
51. 51. Abenhaim L, Moride Y, Brenot F, et al. Appetite suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609-16
52. 52. The International Primary Pulmonary Hypertension Study (IPPHS). Chest 1994; 105 Suppl.: 37S-41S
53. 53. Manson JE, Faich GA. Pharmacotherapy for obesity - do the benefits outweigh the risks? N Engl J Med 1996; 335: 659-60
54. 54. Weissman NJ. Prevalence of valvular abnormalities in patients exposed to dexfenfluramine - result of a randomized placebo-controlled trial. Presented at the 47th Annual American College of Cardiology meeting; 1998 Mar 29-Apr 1; Atlanta
55. 55. Levine LR, Enas GG, Thompson WL, et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. Int J Obesity 1989; 13: 635-45
56. 56. Piji H, Koppeschaar HPF, Willekens FLA, et al. Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. Int J Obesity 1991; 15: 237-42
57. 57. Darga LL, Carroll-Michals L, Botsford SJ, et al. Fluoxetine's effect on weight loss in obese subjects. Am J Clin Nutr 1991; 54: 321-5
58. 58. Goldstein DJ, Rampey AH, Enas GG, et al. Fluozetine: a randomized clinical trial in the treatment of obesity. Int J Obesity 1994; 18: 129-35
59. 59. Gray DS, Fujioka K, Devine W, et al. Fluoxetine treatment of the obese diabetic. Int J Obesity 1992; 16: 193-8
60. 60. Weiser M, Frishman WH, Michaelson Md, et al. The pharmacologic approach to the treatment of obesity. J Clin Pharmacol 1997; 37: 453-73
61. 61. Kelly F, Jones SP, Lee IK. Sibutramine: weight loss in depressed patients [abstract]. Int J Obes 1995; 19 Suppl. 2: 145
62. 62. Weintraub M, Rubio A, Golika A, et al. Sibutramine in weight control: a dose-ranging, efficacy study. Clin Pharmacol Ther 1991; 50: 300-7
63. 63. Ryan DH, Kaiser P, Bray GA. Sibutramine: a novel new agent for obesity treatment. Obes Res 1995; 3 Suppl. 4: 553S-9S
64. 64. Bray GA, Ryan DH, Dordon D. et al. A double-blind, randomized placebo-controlled trial of sibutramine. Obes Res 1996; 4: 263-70
65. 65. Ryan DH, Bray GA, Wilson JK, et al. Treatment for 21/2 years with sibutramine [abstract]. Obes Res 1996; 4 Suppl. 1: 31S
66. 66. Jones SP, Smith IG, Kelly F, et al. Long-term weight loss with sibutramine. Int J Obes 1995; 19 Suppl. 2: 41
67. 67. Lean MEJ. Sibutramine - a review of clinical efficacy. Int J Obes 1997; 21: S30-6
68. 68. Astrup A, Toubro S, Christensen NJ, et al. Pharmacology of thermogenic drugs. Am J Clin Nutr 1992; 55 Suppl.: 246S-8S
69. 69. Quaade F, Breum L, Toubro S, et al. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in the treatment of human obesity: a double-blind trial [abstract]. Int J Obes 1990; 14: 50
70. 3-adrenoreceptor mRNA in human tissues. Eur J Pharmacol 1995; 289: 223-8
71. 71. Arch JRS, Wilson S. Prospects of β3-adreneceptor agonists in the treatment of obesity and diabetes. Int J Obes 1996; 20: 191-9
72. 3-adrenergic receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 1995; 333: 348-51
73. 73. Arch JRS, Ainsworth AT. Thermogenic and antiobesity activity of a novel β-adrenoceptor agonist (BRL 26830A) in mice and rats. Am J Clin Nutr 1983; 38: 549-58
74. 74. Arch JRS, Ainsworth AT, Cawthorne MA, et al. Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 1984; 309: 163-5
75. 75. Arch JRS, Ainsworth AT, Ellis RDM, et al. Treatment of obesity with thermogenic β-adrenoceptor agonists: studies on BRL 26830A in rodents. Int J Obes 1985; 9: 231
76. 76. Thurlby PL, Ellis RDM. Differences between the effects of noradrenaline and the β-adrenoceptor agonist BRL 26830A in brown adipose tissue and hind limb of the anaesthetized rat. Can J Physiol Pharmacol 1986; 64: 1111-4
77. 77. Connacher AA, Jung RT, Mitchell PEG. Weight loss in obese subjects on a restricted diet given BRL 26830A, a new atypical β-adrenoceptor agonist. BMJ 1988; 296: 1217-20
78. 78. Aronne, LJ. Obesity. Med Clin North Am 1998; 82 (1): 161-81
79. 79. Drent ML, van der Veen EA. Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes 1993; 17: 241-4
80. 80. Guerciolini R. Mode of action of orlistat. Int J Obes 1997; 21 Suppl. 3: S12-23
81. 81. F-D-C Rep 1997; May 19: 3-5
82. 82. Drent ML, Larsson I, William-Olsson T, et al. Orlistat (RO 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes 1995; 19: 221-6
83. 83. James WPT, Avenell A, Broom J, et al. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes 1997; 21 Suppl. 3: S24-30
84. 84. Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994; 56: 82-5
85. 85. F-D-C Rep 1998; Mardi 16: 3
86. 86. F-D-C Rep 1998; March 23: 9
87. 87. Weber C, Tam YK, Schmidtke-Schrezenmeier G, et al. Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive agents in healthy volunteers. Eur J Clin Pharmacol 1996; 51: 87-90
88. 88. Melia AT, Mulligan TE, Zhi J. Lack of effect of orlistat on the bioavailability of a single-dose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers. J Clin Pharmacol 1996; 36: 352-5
89. 89. Zhi J, Melia AT, Guerciolini R, et al. The effect of orlistat on the pharmacokinetics und pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 1996; 36: 659-66
90. 90. Melia AT, Zhi J, Koss-Twardy SG, et al. The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 1995; 35: 840-3
91. 91. Melia AT, Mulligan TE, Zhi J. The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. J Clin Pharmacol 1996; 36: 654-8
92. 92. Zhi J, Melia AT, Koss-Twardy SG, et al.The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. J Clin Pharmacol 1995; 35: 521-5
93. 93. Hartman D, Guzelhan C, Zuiderwijk PBM, et al. Lack of interaction between orlistat and oral contraceptives. Eur J Clin Pharmacol 1996; 50: 421-4
94. 94. Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 1996; 36: 647-53
95. 95. Zhi J, Melia AT, Koss-Twardy SG, et al. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. J Clin Pharmacol 1996; 36: 152-9
96. 96. Warshaw H, Franz M, Powers MA, et al. Fat replacers: their use in foods and role in diabetes medical nutrition therapy. Diabetes Care 1996; 11: 1294-300
97. 97. Blackburn H. Olestra and the FDA. N Engl J Med 1996; 334: 984-6
98. 98. Grundy SM, Anastasia JV, Kesaniemi YA, et al. Influence of sucrose polyester on plasma lipoproteins, and cholesterol metabolism in obese patients with and without diabetes mellitus. Am J Clin Nutr 1986; 44: 620-9
99. 99. Glueck CJ, Jandacek R, Hogg E, et al. Sucrose polyester: substitution for dietary fats in hypocaloric diets in the treatment of familial hypercholesterolemia. Am J Clin Nutr 1983; 37: 347-54
100. 100. Mellies MJ, Vitalie C, Jandacek RJ, et al. The substitution of sucrose polyester for dietary fat in obese, hypercholesterolemic outpatients. Am J Clin Nutr 1985; 41: 1-12
101. 101. Glueck CH, Hastings MM, Allen C, et al. Sucrose polyester and covert caloric dilution. Am J Clin Nutr 1982; 35: 1352-9
102. 102. Cotton JR, Westrate JA, Blundell JE. Replacement of dietary fat with sucrose polyester: effects on energy intake and appetite control in non-obese males. Am J Clin Nutr 1996; 63: 891-6
103. 103. Cheskin LJ, Miday R, Zorich N, et al. Gastrointestinal symptoms following consumption of olestra or regular triglyceride potato chips: a controlled comparison. JAMA 1998; 279 (2): 150-2
104. 104. Aggarwal AM, Camilleri M, Phillips SF, et al. Olestra, a non-digestible, nonabsorbable fat. Effects on gastrointestinal and colonic transit. Dig Dis Sci 1993, 38: 1009-14
105. 105. Zorich NL, Jones MB, Kesler JM, et al. A randomized, double-blind study of the effect of olestra on disease activity in patients with quiescent inflammatory bowel disease. Olestra in IBD study group. Am J Med 1997, 103 (5): 389-99
106. 106. Freston JW, Ahnen DJ, Czinn SJ, et al. Review and analysis of the effects of olestra, a dietary fat substitute, on gastrointestinal function and symptoms. Regul Toxicol Pharmacol 1997; 26 (2): 210-8
107. 107. Jones DY, Koonsvitsky BP, Ebert ML, et al. Vitamin K status of free-living subjects consuming olestra. Am J Clin Nutr 1991; 53: 943-6
108. 108. Schlagheck TG, Riccardi KA, Zorich NL, et al. Olestra dose response on fat-soluble and water-soluble nutrients in humans. J Nutrition 1997; 127 Suppl. 8: 1646S-65S
109. 109. Koonsvitsky BP, Berry DA, Jones B, et al. Olestra affects serum concentrations of alpha-tocopherol and carotenoids but not vitamin D or vitamin K status in free-living subjects. J Nutrition 1997; 127 Suppl. 8: 1636S-45S
110. 110. Schlagheck TG, Kesler JM, Jones MB, et al. Olestra's effect on vitamins D und E in humans can be offset by increasing dietary levels of these vitamins. J Nutrition 1997; 127 Suppl. 8: 1666S-85S
111. 111. Jones DY, Miller KW, Koonsvistky BP, et al. Serum 25-hydroxyvitamin D concentrations of free-living subjects consuming olestra. Am J Clin Nutr 1991; 53: 1281-7
112. 112. Fallat RW, Glueck CJ, Lutmer R, et al. Short term study of sucrose polyester a nonabsorbable fat-like material as a dietary agent for lowering plasma cholesterol. Am J Clin Nutr 1976; 29: 1204-15
113. 113. Glueck CJ, Mattson FH, Jandacek RJ. The lowering of plasma cholesterol by sucrose polyester in subjects consuming diets with 800, 300, or less than 50mg of cholesterol per day. Am J Clin Nutr 1979; 32: 1636-44
114. 114. Westrate JA, van bet Hof KH. Sucrose polyester and plasma carotenoid concentrations in healthy subjects. Am J Clin Nutr 1995; 62: 591-7
115. 115. Roberts RJ, Leff RD. Influence of absorbable and nonabsorbable lipids and lipid like substances on drug bioavailability. Clin Pharmacol Ther 1989; 45: 299-304
116. 116. Miller KW, Williams DS, Carter SB, et al. The effect of olestra on systemic levels of oral contraceptives. Clin Pharmacol Ther 1990; 48: 34-40
117. 117. Leibowitz SF. Brain peptides and obesity: pharmacologic treatment. Obes Res 1995; 3 Suppl. 4; 573S-89S
118. 118. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-32
119. 119. Auwerx J, Stacls B. Leptin. Lancet 1998; 351: 737-42
120. 120. Bray GA. Leptin and leptinomania. Lancet 1996; 348: 140-1
121. 121. Caro JF, Sinba MK, Kolaczynski JW, et al. Leptin: the tale of an obesity gene. Diabetes 1996; 45: 1455-62
122. 122. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-5
123. 123. Caro JF, Kolaczynski JW, Nyce MR, et al. Decreased cerebro-spinal-fluid/serum leptin ratio in obesity: a possible mechanism for leplin resistance. Lancet 1996; 348: 159-61
124. 124. Widjaja A, Stratton IM, Horn R, et al. UKPDS 20: plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects. J Clin Endocrinol Metab 1997; 82: 654-7
125. 125. Nolan JJ, Olefsky JM, Nyce MR, et al. Effect of troglitazone on leptin production. Studies in vitro and in human subjects. Diabetes 1996; 45: 1276-8